<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01929642</url>
  </required_header>
  <id_info>
    <org_study_id>AM00037881</org_study_id>
    <nct_id>NCT01929642</nct_id>
  </id_info>
  <brief_title>Rapalogues for Autism Phenotype in TSC: A Feasibility Study</brief_title>
  <acronym>RAPT</acronym>
  <official_title>Rapalogues for Autism Phenotype in TSC: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility and safety of administering&#xD;
      rapalogues, sirolimus or everolimus, in participants with Tuberous Sclerosis Complex (TSC)&#xD;
      and self-injury and to measure cognitive and behavioral changes, including reduction in&#xD;
      autistic symptoms, self-injurious and aggressive behaviors, as well as improvements in&#xD;
      cognition across multiple domains of cognitive function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a feasibility and safety study primarily designed to assess the feasibility and&#xD;
      safety of conducting a larger clinical trial with sirolimus in individuals with TSC. The&#xD;
      present study will employ an ABA design in which three pediatric participants will be&#xD;
      selected to receive baseline medical, developmental, behavioral, and cognitive evaluations,&#xD;
      followed by a 26 week administration of sirolimus, repeated baseline assessments at the end&#xD;
      of the 26 week treatment phase, and a 4 week titrated withdrawal followed by a 22 week period&#xD;
      in which no rapalogue is administered. All participants will again be administered baseline&#xD;
      medical, behavioral, and cognitive evaluations at the end of the study in order to compare&#xD;
      all evaluations done at baseline, the end of the 26 week treatment, and completion of the&#xD;
      study. These comparisons will be done to assess secondary outcomes that include reductions in&#xD;
      autistic symptoms, self-injury, and aggression, as well as improvements in cognitive function&#xD;
      across multiple domains. Furthermore, administration of the secondary outcome measures will&#xD;
      also allow us to better understand the sensitivity of these measures in patients with TSC&#xD;
      during the course of a clinical trial.&#xD;
&#xD;
      Families of potentially eligible children who express interest in the study and meet&#xD;
      prescreening criteria will be invited to attend a screening visit to determine eligibility,&#xD;
      inclusion/exclusion criteria, and availability for eight additional study visits. Prior to&#xD;
      enrollment, informed consent will be obtained from the parent or legal guardian.&#xD;
&#xD;
      Investigators will use the methods of analysis of single-subject research (ABA design, where&#xD;
      first A represents baseline, B represents treatment, and A represents reversal of treatment.&#xD;
      The analysis will focus on each of the 3 subjects separately. Data on feasibility and safety&#xD;
      (primary outcome) and on frequency of disruptive behavior (secondary outcome) will be plotted&#xD;
      and visually inspected to detect any temporal changes by phase: 1. Baseline, 2. Treatment, 3.&#xD;
      After treatment. Data in each phase will be summarized as mean +/- standard deviation (SD).&#xD;
      We will use the summary data to assess the potential effect of the intervention. Consistency&#xD;
      of the effect will be examined across the 3 study participants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Compliance to the Treatment Protocol.</measure>
    <time_frame>Change from baseline to EOT visit 12 week 53</time_frame>
    <description>One outcome measurement of feasibility will include family/patient compliance with the treatment protocol, which will be assessed and documented at every study visit and telephone follow-up call, by the physician and/or study team member. This was calculated by calculating dividing the total number of study visits and study assessments completed by the total number of study visits and study assessments indicated by the treatment protocol.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caregiver Burden</measure>
    <time_frame>Change from baseline to EOT visit 12 week 53</time_frame>
    <description>The Caregiver Burden Scale is a standard set of questions which will be used to measure the non-medical impact of TSC on caregivers and how it affects the feasibility of study completion.&#xD;
The Caregiver's Burden Scale (CBS) is a 22-item scale that assess subjectively experienced burden by caregiver's to chronically disabled persons. maximum scores: 88 &amp; Minumum scores: 22&#xD;
High values represent a worse outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility Measurements of Parental Stress</measure>
    <time_frame>Change from baseline to EOT visit 12 week 53</time_frame>
    <description>Measurements of stress will be administered. Specifically, we will use the Parental Stress Index. Quantifying stress, as well as compliance with the study protocol, will allow investigators to objectively assess the feasibility of a larger clinical trial of sirolimus in patients with TSC.&#xD;
Parental stress index maximum score: 180 Parental stress index minimum score: 36 higher raw scores indicate higher levels of stress.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Number of Aggressions or Self-injuries</measure>
    <time_frame>1 year</time_frame>
    <description>This is the total number of aggressions or self-injuries for all participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function as Assessed by the Capute Scale</measure>
    <time_frame>1 year</time_frame>
    <description>Score range maximum: 100 Score range minimum: 0&#xD;
High values represent a high cognitive function Below 70 is abnormal. 70-100 is the normal range.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repetitive Behavior</measure>
    <time_frame>1 year</time_frame>
    <description>Repetitive behavior will be assessed using the Repetitive Behavior Scale - revised, a questionnaire to characterize several domains of repetitive behavior including ritualistic behavior, stereotypic behavior, self-injurious behavior, compulsive behavior, and restricted interests.&#xD;
There are 36 items on the scale. Behaviors are rated on a 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem.&#xD;
Maximum score: 108 &amp; minimum score: 0 A high score represents the worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Injury Trauma Scale--SIT Scale</measure>
    <time_frame>1 year</time_frame>
    <description>The SIT Scale is a 3-part clinician-completed scale used to quantify visible injuries caused by self-injurious behavior(SIB). Part 1 includes sections to indicate SIB topographies and any evidence of healed injury. In Part 2 evaluators document the location and severity of injury (on a 3-point scale). In Part 3, respective scores from Parts 1 and 2 are summed to obtain a Number Index, a Severity Index, and Estimate of Current Risk. This Scale has been used in research with adults with SIB with inter-rater reliability averaging 85%.&#xD;
Maximum score: 100 Minimum score: 0 High score represent worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Seizures Assessed by Total Number of Seizures</measure>
    <time_frame>at baseline</time_frame>
    <description>Parents will be asked to document the frequency of their child's seizures using a manual or electronic (seizuretracker.com) seizure diary. The total number of seizures at baseline for all participants.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Tuberous Sclerosis Complex</condition>
  <condition>Self-injury</condition>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>Sirolimus or Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <arm_group_label>Sirolimus or Everolimus</arm_group_label>
    <other_name>Rapamune, Rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>Sirolimus or Everolimus</arm_group_label>
    <other_name>Afinitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with Tuberous Sclerosis Complex as defined by the revised NIH consensus&#xD;
             criteria&#xD;
&#xD;
          2. Possible autism or autism spectrum disorder and/or possible intellectual disability&#xD;
             and/or global developmental delay&#xD;
&#xD;
          3. Currently displaying disruptive behaviors, such as self-injury and aggression&#xD;
&#xD;
          4. Seizures or epilepsy with at least one seizure within six months prior to enrollment&#xD;
&#xD;
          5. 2-30 years of age&#xD;
&#xD;
          6. English-speaking caregiver if participant is non-verbal.&#xD;
&#xD;
          7. If individuals are currently being treated with everolimus, they must have been taking&#xD;
             it for less than or equal to 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participants who require live vaccines that are contraindicated with sirolimus will be&#xD;
             excluded - bacille Calmette Guerin(BCG), measles-mumps-rubella vaccine(MMR),&#xD;
             poliovirus, rotavirus, smallpox, typhoid, varicella, or yellow fever.&#xD;
&#xD;
          2. Participants who have a history of multiple or severe infections, or reside in a&#xD;
             household with anyone who has a chronic, contagious condition will be excluded.&#xD;
             Multiple infections will be defined as eight or more lifetime episodes of otitis media&#xD;
             or two or more lifetime episodes of bacterial pneumonia. Severe infections will be&#xD;
             defined as infections requiring more than one hospital admission for treatment.&#xD;
&#xD;
          3. Participants with any of the following laboratory abnormalities will be excluded:&#xD;
             hematocrit &lt; 27%, absolute neutrophil count(ANC) &lt; 1,500, platelet count &lt; 100,000,&#xD;
             serum glutamate oxaloacetate transaminase(SGOT) or serum glutamate pyruvate&#xD;
             transaminase (SGPT) &gt; two times normal for age, bilirubin &gt; two times normal for age,&#xD;
             alkaline phosphatase &gt; two times normal for age, epidermal growth factor receptor&#xD;
             (eGFR) &lt; 30, or evidence of renal failure, hypercholesterolemia.&#xD;
&#xD;
          4. Participants who have medical contraindications to undergoing an MRI will be excluded.&#xD;
&#xD;
          5. Participants with devices implanted in the brain will be excluded.&#xD;
&#xD;
          6. Pregnant participants will be excluded. All young ladies of child bearing potential&#xD;
             will have a blood test for pregnancy prior to the start of the study and every study&#xD;
             visit for the duration of the study.&#xD;
&#xD;
          7. Participants who have a history of herpes simplex virus, cytomegalovirus, and/or HIV&#xD;
             infection will be excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanjala Gipson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hugo W. Moser Research Institute at Kennedy Krieger, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kennedy Krieger Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.kennedykrieger.org/research-training/participate-in-research/clinical-trials</url>
    <description>Kennedy Krieger Institute Clinical Trials Unit</description>
  </link>
  <link>
    <url>http://www.kennedykrieger.org/patient-care/patient-care-programs/outpatient-programs/tuberous-sclerosis-clinic</url>
    <description>TSC clinic at Kennedy Krieger Institute</description>
  </link>
  <reference>
    <citation>Napolioni V, Curatolo P. Genetics and molecular biology of tuberous sclerosis complex. Curr Genomics. 2008 Nov;9(7):475-87. doi: 10.2174/138920208786241243.</citation>
    <PMID>19506736</PMID>
  </reference>
  <reference>
    <citation>Gomez M, Sampson JR, Whittemore VH, editors. Tuberous sclerosis complex. 3rd ed. Oxford University Press; 1999.</citation>
  </reference>
  <reference>
    <citation>Osborne JP, Fryer A, Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci. 1991;615:125-7.</citation>
    <PMID>2039137</PMID>
  </reference>
  <reference>
    <citation>Cross JH. Neurocutaneous syndromes and epilepsy-issues in diagnosis and management. Epilepsia. 2005;46 Suppl 10:17-23. Review.</citation>
    <PMID>16359466</PMID>
  </reference>
  <reference>
    <citation>Curatolo P, Bombardieri R, Verdecchia M, Seri S. Intractable seizures in tuberous sclerosis complex: from molecular pathogenesis to the rationale for treatment. J Child Neurol. 2005 Apr;20(4):318-25. Review.</citation>
    <PMID>15921233</PMID>
  </reference>
  <reference>
    <citation>Joinson C, O'Callaghan FJ, Osborne JP, Martyn C, Harris T, Bolton PF. Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex. Psychol Med. 2003 Feb;33(2):335-44.</citation>
    <PMID>12622312</PMID>
  </reference>
  <reference>
    <citation>de Vries PJ. Targeted treatments for cognitive and neurodevelopmental disorders in tuberous sclerosis complex. Neurotherapeutics. 2010 Jul;7(3):275-82. doi: 10.1016/j.nurt.2010.05.001. Review.</citation>
    <PMID>20643380</PMID>
  </reference>
  <reference>
    <citation>Smalley SL. Autism and tuberous sclerosis. J Autism Dev Disord. 1998 Oct;28(5):407-14. Review.</citation>
    <PMID>9813776</PMID>
  </reference>
  <reference>
    <citation>Bolton PF, Park RJ, Higgins JN, Griffiths PD, Pickles A. Neuro-epileptic determinants of autism spectrum disorders in tuberous sclerosis complex. Brain. 2002 Jun;125(Pt 6):1247-55.</citation>
    <PMID>12023313</PMID>
  </reference>
  <reference>
    <citation>Prescibing Information for Sirolimus. 1999).</citation>
  </reference>
  <reference>
    <citation>Sindhi R. Sirolimus in pediatric transplant recipients. Transplant Proc. 2003 May;35(3 Suppl):113S-114S.</citation>
    <PMID>12742479</PMID>
  </reference>
  <reference>
    <citation>Ehninger D, Han S, Shilyansky C, Zhou Y, Li W, Kwiatkowski DJ, Ramesh V, Silva AJ. Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis. Nat Med. 2008 Aug;14(8):843-8. doi: 10.1038/nm1788. Epub 2008 Jun 22.</citation>
    <PMID>18568033</PMID>
  </reference>
  <reference>
    <citation>Zeng LH, Xu L, Gutmann DH, Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol. 2008 Apr;63(4):444-53. doi: 10.1002/ana.21331.</citation>
    <PMID>18389497</PMID>
  </reference>
  <reference>
    <citation>Franz DN, Leonard J, Tudor C, Chuck G, Care M, Sethuraman G, Dinopoulos A, Thomas G, Crone KR. Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol. 2006 Mar;59(3):490-8.</citation>
    <PMID>16453317</PMID>
  </reference>
  <reference>
    <citation>Krueger DA, Care MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T, Franz DN. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med. 2010 Nov 4;363(19):1801-11. doi: 10.1056/NEJMoa1001671.</citation>
    <PMID>21047224</PMID>
  </reference>
  <reference>
    <citation>Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011 Jun 15;17(12):4071-81. doi: 10.1158/1078-0432.CCR-11-0445. Epub 2011 Apr 27.</citation>
    <PMID>21525172</PMID>
  </reference>
  <reference>
    <citation>Meikle L, Pollizzi K, Egnor A, Kramvis I, Lane H, Sahin M, Kwiatkowski DJ. Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function. J Neurosci. 2008 May 21;28(21):5422-32. doi: 10.1523/JNEUROSCI.0955-08.2008.</citation>
    <PMID>18495876</PMID>
  </reference>
  <reference>
    <citation>McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Young LR, Kinder BW, Downey GP, Sullivan EJ, Colby TV, McKay RT, Cohen MM, Korbee L, Taveira-DaSilva AM, Lee HS, Krischer JP, Trapnell BC; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011 Apr 28;364(17):1595-606. doi: 10.1056/NEJMoa1100391. Epub 2011 Mar 16.</citation>
    <PMID>21410393</PMID>
  </reference>
  <reference>
    <citation>Flaig TW, Costa LJ, Gustafson DL, Breaker K, Schultz MK, Crighton F, Kim FJ, Drabkin H. Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib. Br J Cancer. 2010 Sep 7;103(6):796-801. doi: 10.1038/sj.bjc.6605868.</citation>
    <PMID>20823888</PMID>
  </reference>
  <reference>
    <citation>Asrani SK, Leise MD, West CP, Murad MH, Pedersen RA, Erwin PJ, Tian J, Wiesner RH, Kim WR. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology. 2010 Oct;52(4):1360-70. doi: 10.1002/hep.23835. Review.</citation>
    <PMID>20815021</PMID>
  </reference>
  <reference>
    <citation>Armstrong AJ, Netto GJ, Rudek MA, Halabi S, Wood DP, Creel PA, Mundy K, Davis SL, Wang T, Albadine R, Schultz L, Partin AW, Jimeno A, Fedor H, Febbo PG, George DJ, Gurganus R, De Marzo AM, Carducci MA. A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer. Clin Cancer Res. 2010 Jun 1;16(11):3057-66. doi: 10.1158/1078-0432.CCR-10-0124. Epub 2010 May 25.</citation>
    <PMID>20501622</PMID>
  </reference>
  <reference>
    <citation>Habib SL. Tuberous sclerosis complex and DNA repair. Adv Exp Med Biol. 2010;685:84-94. Review.</citation>
    <PMID>20687497</PMID>
  </reference>
  <reference>
    <citation>Rapamune: U.S. Physician Prescribing Information. 1999).</citation>
  </reference>
  <reference>
    <citation>Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant. 2008 Dec;13(6):563-8. doi: 10.1097/MOT.0b013e3283186ba9. Review.</citation>
    <PMID>19060543</PMID>
  </reference>
  <reference>
    <citation>Novak M, Guest C. Application of a multidimensional caregiver burden inventory. Gerontologist. 1989 Dec;29(6):798-803.</citation>
    <PMID>2516000</PMID>
  </reference>
  <reference>
    <citation>Abidin R. Parental stress index - 4, short form. fourth edition ed. Odessa, FL: Psychological Assessment Resources, Inc.; 2009.</citation>
  </reference>
  <reference>
    <citation>Staley BA, Montenegro MA, Major P, Muzykewicz DA, Halpern EF, Kopp CM, Newberry P, Thiele EA. Self-injurious behavior and tuberous sclerosis complex: frequency and possible associations in a population of 257 patients. Epilepsy Behav. 2008 Nov;13(4):650-3. doi: 10.1016/j.yebeh.2008.07.010. Epub 2008 Aug 30.</citation>
    <PMID>18703161</PMID>
  </reference>
  <reference>
    <citation>Seizuretracker.com [Internet].; 2012.</citation>
  </reference>
  <reference>
    <citation>Roach ES, DiMario FJ, Kandt RS, Northrup H. Tuberous Sclerosis Consensus Conference: recommendations for diagnostic evaluation. National Tuberous Sclerosis Association. J Child Neurol. 1999 Jun;14(6):401-7. Review.</citation>
    <PMID>10385849</PMID>
  </reference>
  <reference>
    <citation>O'Callaghan FJ, Harris T, Joinson C, Bolton P, Noakes M, Presdee D, Renowden S, Shiell A, Martyn CN, Osborne JP. The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex. Arch Dis Child. 2004 Jun;89(6):530-3.</citation>
    <PMID>15155396</PMID>
  </reference>
  <reference>
    <citation>Asano E, Chugani DC, Muzik O, Behen M, Janisse J, Rothermel R, Mangner TJ, Chakraborty PK, Chugani HT. Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction. Neurology. 2001 Oct 9;57(7):1269-77.</citation>
    <PMID>11591847</PMID>
  </reference>
  <reference>
    <citation>Doherty C, Goh S, Young Poussaint T, Erdag N, Thiele EA. Prognostic significance of tuber count and location in tuberous sclerosis complex. J Child Neurol. 2005 Oct;20(10):837-41.</citation>
    <PMID>16417883</PMID>
  </reference>
  <reference>
    <citation>Raznahan A, Higgins NP, Griffiths PD, Humphrey A, Yates JR, Bolton PF. Biological markers of intellectual disability in tuberous sclerosis. Psychol Med. 2007 Sep;37(9):1293-304. Epub 2007 Mar 5.</citation>
    <PMID>17335641</PMID>
  </reference>
  <reference>
    <citation>Roid G, Miller L. Leiter international performance scale, revised. Torrance, CA: Western Psychological Services; 1998.</citation>
  </reference>
  <reference>
    <citation>Mullen E. Mullen scales of early learning. Circle Pines, MN: American Guidance Service, Inc.; 1995.</citation>
  </reference>
  <reference>
    <citation>Wachtel RC, Shapiro BK, Palmer FB, Allen MC, Capute AJ. CAT/CLAMS. A tool for the pediatric evaluation of infants and young children with developmental delay. Clinical Adaptive Test/Clinical Linguistic and Auditory Milestone Scale. Clin Pediatr (Phila). 1994 Jul;33(7):410-5.</citation>
    <PMID>7525138</PMID>
  </reference>
  <reference>
    <citation>Iwata BA, Pace GM, Kissel RC, Nau PA, Farber JM. The Self-Injury Trauma (SIT) Scale: a method for quantifying surface tissue damage caused by self-injurious behavior. J Appl Behav Anal. 1990 Spring;23(1):99-110.</citation>
    <PMID>2335488</PMID>
  </reference>
  <reference>
    <citation>Lord C, Risi S, Lambrecht L, Cook EH Jr, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000 Jun;30(3):205-23.</citation>
    <PMID>11055457</PMID>
  </reference>
  <reference>
    <citation>Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994 Oct;24(5):659-85.</citation>
    <PMID>7814313</PMID>
  </reference>
  <reference>
    <citation>Constantino J. The social responsiveness scale. Los Angeles: Western Psychological Services; 2002.</citation>
  </reference>
  <reference>
    <citation>Rutter M, Bailey A, Lord C. Social communication questionnaire. Western Psychological Services; 2003.</citation>
  </reference>
  <reference>
    <citation>Granader YE, Bender HA, Zemon V, Rathi S, Nass R, Macallister WS. The clinical utility of the Social Responsiveness Scale and Social Communication Questionnaire in tuberous sclerosis complex. Epilepsy Behav. 2010 Jul;18(3):262-6. doi: 10.1016/j.yebeh.2010.04.010.</citation>
    <PMID>20554253</PMID>
  </reference>
  <reference>
    <citation>Mirenda P, Smith IM, Vaillancourt T, Georgiades S, Duku E, Szatmari P, Bryson S, Fombonne E, Roberts W, Volden J, Waddell C, Zwaigenbaum L; Pathways in ASD Study Team. Validating the Repetitive Behavior Scale-revised in young children with autism spectrum disorder. J Autism Dev Disord. 2010 Dec;40(12):1521-30. doi: 10.1007/s10803-010-1012-0.</citation>
    <PMID>20405194</PMID>
  </reference>
  <reference>
    <citation>Kazdin AE. Single-case research designs in clinical child psychiatry. J Am Acad Child Psychiatry. 1983 Sep;22(5):423-32.</citation>
    <PMID>6630801</PMID>
  </reference>
  <reference>
    <citation>Sanchez CP, He YZ. Bone growth during rapamycin therapy in young rats. BMC Pediatr. 2009 Jan 13;9:3. doi: 10.1186/1471-2431-9-3.</citation>
    <PMID>19144108</PMID>
  </reference>
  <reference>
    <citation>Alvarez-Garcia O, Carbajo-Pérez E, Garcia E, Gil H, Molinos I, Rodriguez J, Ordoñez FA, Santos F. Rapamycin retards growth and causes marked alterations in the growth plate of young rats. Pediatr Nephrol. 2007 Jul;22(7):954-61. Epub 2007 Mar 17.</citation>
    <PMID>17370095</PMID>
  </reference>
  <reference>
    <citation>Rangel GA, Ariceta G. Growth failure associated with sirolimus: case report. Pediatr Nephrol. 2009 Oct;24(10):2047-50. doi: 10.1007/s00467-009-1215-9. Epub 2009 Jun 3.</citation>
    <PMID>19495804</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <results_first_submitted>April 6, 2018</results_first_submitted>
  <results_first_submitted_qc>March 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2021</results_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tuberous Sclerosis Complex (TSC)</keyword>
  <keyword>self-injury</keyword>
  <keyword>Autism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberous Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Self-Injurious Behavior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus or Everolimus</title>
          <description>Oral solution or tablet,titrated to therapeutic serum trough range (sirolimus); Oral tablet, titrated to therapeutic serum trough range (everolimus)&#xD;
Sirolimus&#xD;
Everolimus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus or Sirolimus</title>
          <description>Medication choice</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7" lower_limit="3" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Compliance to the Treatment Protocol.</title>
        <description>One outcome measurement of feasibility will include family/patient compliance with the treatment protocol, which will be assessed and documented at every study visit and telephone follow-up call, by the physician and/or study team member. This was calculated by calculating dividing the total number of study visits and study assessments completed by the total number of study visits and study assessments indicated by the treatment protocol.</description>
        <time_frame>Change from baseline to EOT visit 12 week 53</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus or Sirolimus</title>
            <description>Medication</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Compliance to the Treatment Protocol.</title>
          <description>One outcome measurement of feasibility will include family/patient compliance with the treatment protocol, which will be assessed and documented at every study visit and telephone follow-up call, by the physician and/or study team member. This was calculated by calculating dividing the total number of study visits and study assessments completed by the total number of study visits and study assessments indicated by the treatment protocol.</description>
          <units>percentage of completed visits/measures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participant 002</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 003</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant 001</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Caregiver Burden</title>
        <description>The Caregiver Burden Scale is a standard set of questions which will be used to measure the non-medical impact of TSC on caregivers and how it affects the feasibility of study completion.&#xD;
The Caregiver's Burden Scale (CBS) is a 22-item scale that assess subjectively experienced burden by caregiver's to chronically disabled persons. maximum scores: 88 &amp; Minumum scores: 22&#xD;
High values represent a worse outcome</description>
        <time_frame>Change from baseline to EOT visit 12 week 53</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus or Sirolimus</title>
            <description>Medication choice</description>
          </group>
        </group_list>
        <measure>
          <title>Caregiver Burden</title>
          <description>The Caregiver Burden Scale is a standard set of questions which will be used to measure the non-medical impact of TSC on caregivers and how it affects the feasibility of study completion.&#xD;
The Caregiver's Burden Scale (CBS) is a 22-item scale that assess subjectively experienced burden by caregiver's to chronically disabled persons. maximum scores: 88 &amp; Minumum scores: 22&#xD;
High values represent a worse outcome</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61" lower_limit="45" upper_limit="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Feasibility Measurements of Parental Stress</title>
        <description>Measurements of stress will be administered. Specifically, we will use the Parental Stress Index. Quantifying stress, as well as compliance with the study protocol, will allow investigators to objectively assess the feasibility of a larger clinical trial of sirolimus in patients with TSC.&#xD;
Parental stress index maximum score: 180 Parental stress index minimum score: 36 higher raw scores indicate higher levels of stress.</description>
        <time_frame>Change from baseline to EOT visit 12 week 53</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus or Sirolimus</title>
          </group>
        </group_list>
        <measure>
          <title>Feasibility Measurements of Parental Stress</title>
          <description>Measurements of stress will be administered. Specifically, we will use the Parental Stress Index. Quantifying stress, as well as compliance with the study protocol, will allow investigators to objectively assess the feasibility of a larger clinical trial of sirolimus in patients with TSC.&#xD;
Parental stress index maximum score: 180 Parental stress index minimum score: 36 higher raw scores indicate higher levels of stress.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111" lower_limit="86" upper_limit="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Aggressions or Self-injuries</title>
        <description>This is the total number of aggressions or self-injuries for all participants.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus or Sirolimus</title>
            <description>Medication choice</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Aggressions or Self-injuries</title>
          <description>This is the total number of aggressions or self-injuries for all participants.</description>
          <units>Number of aggressions or self-injuries</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cognitive Function as Assessed by the Capute Scale</title>
        <description>Score range maximum: 100 Score range minimum: 0&#xD;
High values represent a high cognitive function Below 70 is abnormal. 70-100 is the normal range.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus or Sirolimus</title>
            <description>Medication choice</description>
          </group>
        </group_list>
        <measure>
          <title>Cognitive Function as Assessed by the Capute Scale</title>
          <description>Score range maximum: 100 Score range minimum: 0&#xD;
High values represent a high cognitive function Below 70 is abnormal. 70-100 is the normal range.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="14" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Repetitive Behavior</title>
        <description>Repetitive behavior will be assessed using the Repetitive Behavior Scale - revised, a questionnaire to characterize several domains of repetitive behavior including ritualistic behavior, stereotypic behavior, self-injurious behavior, compulsive behavior, and restricted interests.&#xD;
There are 36 items on the scale. Behaviors are rated on a 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem.&#xD;
Maximum score: 108 &amp; minimum score: 0 A high score represents the worse outcome</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus or Sirolimus</title>
            <description>Medication choice</description>
          </group>
        </group_list>
        <measure>
          <title>Repetitive Behavior</title>
          <description>Repetitive behavior will be assessed using the Repetitive Behavior Scale - revised, a questionnaire to characterize several domains of repetitive behavior including ritualistic behavior, stereotypic behavior, self-injurious behavior, compulsive behavior, and restricted interests.&#xD;
There are 36 items on the scale. Behaviors are rated on a 4-point scale: 0-Behavior does not occur, 1-Behavior occurs and is a mild problem, 2-Behavior occurs and is a moderate problem, 3-Behavior occurs and is a severe problem.&#xD;
Maximum score: 108 &amp; minimum score: 0 A high score represents the worse outcome</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="58" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Self-Injury Trauma Scale--SIT Scale</title>
        <description>The SIT Scale is a 3-part clinician-completed scale used to quantify visible injuries caused by self-injurious behavior(SIB). Part 1 includes sections to indicate SIB topographies and any evidence of healed injury. In Part 2 evaluators document the location and severity of injury (on a 3-point scale). In Part 3, respective scores from Parts 1 and 2 are summed to obtain a Number Index, a Severity Index, and Estimate of Current Risk. This Scale has been used in research with adults with SIB with inter-rater reliability averaging 85%.&#xD;
Maximum score: 100 Minimum score: 0 High score represent worse outcome.</description>
        <time_frame>1 year</time_frame>
        <population>Self-injury was not severe enough to use the scale. Therefore analysis was not done.</population>
        <group_list>
          <group group_id="O1">
            <title>Everolimus or Sirolimus</title>
          </group>
        </group_list>
        <measure>
          <title>Self-Injury Trauma Scale--SIT Scale</title>
          <description>The SIT Scale is a 3-part clinician-completed scale used to quantify visible injuries caused by self-injurious behavior(SIB). Part 1 includes sections to indicate SIB topographies and any evidence of healed injury. In Part 2 evaluators document the location and severity of injury (on a 3-point scale). In Part 3, respective scores from Parts 1 and 2 are summed to obtain a Number Index, a Severity Index, and Estimate of Current Risk. This Scale has been used in research with adults with SIB with inter-rater reliability averaging 85%.&#xD;
Maximum score: 100 Minimum score: 0 High score represent worse outcome.</description>
          <population>Self-injury was not severe enough to use the scale. Therefore analysis was not done.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Seizures Assessed by Total Number of Seizures</title>
        <description>Parents will be asked to document the frequency of their child's seizures using a manual or electronic (seizuretracker.com) seizure diary. The total number of seizures at baseline for all participants.</description>
        <time_frame>at baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus or Sirolimus</title>
            <description>Medication choice</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Seizures Assessed by Total Number of Seizures</title>
          <description>Parents will be asked to document the frequency of their child's seizures using a manual or electronic (seizuretracker.com) seizure diary. The total number of seizures at baseline for all participants.</description>
          <units>seizures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Everolimus</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>aphthous ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Tanjala Gipson</name_or_title>
      <organization>Boling Center for Developmental Disabilities</organization>
      <phone>901-448-6512</phone>
      <email>sbarden@uthsc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

